You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

47 Results
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Sep 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Sep 2025
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV Melanoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Sep 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Drugs Used:
pembrolizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Sep 2025
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pembrolizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Sep 2025
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Endocrine, 
Adrenal, 
Neuroendocrine, 
Pancreatic Neuroendocrine, 
Parathyroid, 
Thymoma, 
Thyroid, 
Gastrointestinal, 
Anus, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Gastrointestinal Stromal Tumours, 
Hepatobiliary / Liver / Bile Duct, 
Mesothelioma (Peritoneal), 
Neuroendocrine (GI), 
Pancreas, 
Rectal, 
Small bowel and appendix, 
Genitourinary, 
Bladder / Urothelial, 
Penile, 
Prostate, 
Renal cell / Kidney, 
Testis, 
Gynecologic, 
Cervix, 
Endometrial, 
Germ Cell, 
Gestational Trophoblastic Disease, 
Ovary, 
Uterine Sarcoma, 
Vagina, 
Vulva, 
Head and Neck, 
Larynx, 
Nasopharynx, 
Oral, 
Paranasal Sinus, 
Pharynx, 
Salivary Gland, 
Squamous Cell, 
Kaposi's Sarcoma, 
Lung, 
Mesothelioma (Pleural), 
Neuroendocrine (Lung), 
Non-Small Cell, 
Small Cell, 
Mesothelioma, 
Ocular / Eye, 
Sarcoma, 
Desmoid Tumour, 
Ewing's, 
Ewing's and Soft Tissue, 
GIST, 
Giant Cell Tumour, 
Kaposi's Sarcoma, 
Osteogenic / Bone, 
Soft Tissue, 
Uterine, 
Wilm's Tumour, 
Skin, 
Basal Cell, 
Melanoma, 
Merkel Cell, 
Squamous Cell, 
Unknown Primary
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab (Adult and Pediatric) - Unresectable or Metastatic MSI-H or dMMR Advanced Solid Tumours
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Sep 2025
Drug
Other Name(s): Scemblix™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Sep 2025
Drug
Other Name(s): Tibsovo®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Azacitidine in combination with Ivosidenib (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Exceptional Access Program
    Ivosidenib in combination with Azacitidine (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ivosidenib,
azaCITIDine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
Sep 2025
Drug
Other Name(s): Vidaza®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Sep 2025

Pages